166 results on '"Piliero, Peter"'
Search Results
2. Medical Affairs Careers
3. Appropriate Use of Nevirapine for Long-Term Therapy [with Reply]
4. Boosted Tipranavir versus Darunavir in Treatment-Experienced Patients: Observational Data from the Randomized POTENT Trial
5. Ritonavir-Boosted Protease Inhibitors: Impact of Ritonavir on Toxicities in Treatment-Experienced Patients
6. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks
7. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen into 1 and 2 clinical trials
8. Strategies for initiating combination antiretroviral therapy
9. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors
10. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
11. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects
12. Susceptibility of HIV-1 to Tipranavir and Other Antiretroviral Agents in Treatment-Experienced Patients: The UTILIZE Study
13. Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects
14. Atazanavir: profile report
15. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults
16. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers
17. Implementing a Standardized HIV Antiretroviral Order Form May Reduce Medication Errors
18. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial
19. T cells containing T cell receptor excision circles are inversely related to HIV replication and are selectively and rapidly released into circulation with antiretroviral treatment
20. Atazanavir: A Viewpoint by Peter J. Piliero
21. Ritonavir-associated hyperparathyroidism, osteopenia and bone pain
22. The utility of inhibitory quotients in determining the relative potency of protease inhibitors
23. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers
24. Isoniazid-Induced β-Hydroxybutyric Acidosis
25. Pharmacodynamics and clinical use of anti-HIV drugs
26. 251. Evaluation of drug-related problems in an outpatient HIV clinic.
27. Acute uveitis associated with rifabutin use in patients with human immunodeficiency virus infection
28. Susceptibility of HIV-1 to Tipranavir and Other Antiretroviral Agents in Treatment-Experienced Patients: The UTILIZE Study
29. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
30. Pharmacokinetic Assessment of Nevirapine and Metabolites in Human Immunodeficiency Virus Type 1-Infected Patients with Hepatic Fibrosis
31. Effect of Ritonavir-Boosted Tipranavir or Darunavir on the Steady-State Pharmacokinetics of Elvitegravir
32. Efficacy And Safety of Three Doses of Tipranavir Boosted with Ritonavir in Treatment-Experienced HIV Type 1-Infected Patients
33. Interaction between Fosamprenavir, with and without Ritonavir, and Nevirapine in Human Immunodeficiency Virus-Infected Subjects
34. Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials
35. Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks
36. Appropriate Use of Nevirapinefor Long‐Term Therapy
37. Atazanavir—A Once-daily HIV Protease Inhibitor That Does Not Cause Dyslipidemia in Newly Treated Patients: Results from Two Randomized Clinical Trials
38. In Vitro-In Vivo Model for Evaluating the Antiviral Activity of Amprenavir in Combination with Ritonavir Administered at 600 and 100 Milligrams, Respectively, Every 12 Hours
39. Simplified Regimens for Treating HIV Infection and AIDS
40. Guillain‐Barre Syndrome Associated with Immune Reconstitution
41. Early Factors in Successful Anti-HIV Treatment
42. Atazanavir: a novel HIV-1 protease inhibitor
43. Interaction between ritonavir and statins
44. An Assessment of Herbal Therapy Use, Adherence and Utilization of Pharmacy Services in HIV Clinics
45. Increasing Treatment Adherence in the Correctional Setting: Current Efforts to Simplify Protease Inhibitor Dosing Regimens
46. Pulmonary zygomycosis after allogeneic bone marrow transplantation
47. Pulmonary Zygomycosis After Allogeneic Bone Marrow Transplantation
48. Functional asplenia in systemic lupus erythematosus
49. Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks.
50. Eastern Equine Encephalitis Presenting as Focal Neuroradiographic Abnormalities: Case Report and Review.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.